JP2024540152A5 - - Google Patents
Info
- Publication number
- JP2024540152A5 JP2024540152A5 JP2024525557A JP2024525557A JP2024540152A5 JP 2024540152 A5 JP2024540152 A5 JP 2024540152A5 JP 2024525557 A JP2024525557 A JP 2024525557A JP 2024525557 A JP2024525557 A JP 2024525557A JP 2024540152 A5 JP2024540152 A5 JP 2024540152A5
- Authority
- JP
- Japan
- Prior art keywords
- ctla
- antibody
- therapeutic agent
- agent according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163273660P | 2021-10-29 | 2021-10-29 | |
| US63/273,660 | 2021-10-29 | ||
| PCT/US2022/078875 WO2023077069A1 (en) | 2021-10-29 | 2022-10-28 | Anti-ctla-4 antibody dosing regimens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540152A JP2024540152A (ja) | 2024-10-31 |
| JP2024540152A5 true JP2024540152A5 (enExample) | 2025-11-07 |
Family
ID=86158833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525557A Pending JP2024540152A (ja) | 2021-10-29 | 2022-10-28 | 抗ｃｔｌａ－４抗体投与レジメン |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4422685A4 (enExample) |
| JP (1) | JP2024540152A (enExample) |
| KR (1) | KR20240099187A (enExample) |
| CN (1) | CN118176021A (enExample) |
| AU (1) | AU2022377644A1 (enExample) |
| CA (1) | CA3234351A1 (enExample) |
| MX (1) | MX2024004429A (enExample) |
| TW (1) | TW202325738A (enExample) |
| WO (1) | WO2023077069A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121358769A (zh) * | 2023-05-17 | 2026-01-16 | 昂科医药 | Ph敏感性抗ctla-4抗体及其用途 |
| WO2026041780A2 (en) * | 2024-08-23 | 2026-02-26 | BioNTech SE | Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8110194B2 (en) * | 2005-12-07 | 2012-02-07 | Medarex, Inc. | CTLA-4 antibody dosage escalation regimens |
| EP2912063A1 (en) * | 2012-10-23 | 2015-09-02 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| PL3142751T3 (pl) * | 2014-05-13 | 2019-12-31 | Medimmune Limited | Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca |
| ES2979210T3 (es) | 2015-12-15 | 2024-09-24 | Oncoc4 Inc | Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos |
| TWI799432B (zh) * | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| JP2021513540A (ja) * | 2018-02-13 | 2021-05-27 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
-
2022
- 2022-10-28 JP JP2024525557A patent/JP2024540152A/ja active Pending
- 2022-10-28 EP EP22888534.9A patent/EP4422685A4/en active Pending
- 2022-10-28 CN CN202280072636.XA patent/CN118176021A/zh active Pending
- 2022-10-28 KR KR1020247012748A patent/KR20240099187A/ko active Pending
- 2022-10-28 CA CA3234351A patent/CA3234351A1/en active Pending
- 2022-10-28 TW TW111141150A patent/TW202325738A/zh unknown
- 2022-10-28 MX MX2024004429A patent/MX2024004429A/es unknown
- 2022-10-28 WO PCT/US2022/078875 patent/WO2023077069A1/en not_active Ceased
- 2022-10-28 AU AU2022377644A patent/AU2022377644A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| Van Cutsem et al. | A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients | |
| JP2023502929A5 (enExample) | ||
| JP2024540152A5 (enExample) | ||
| CN118267469A (zh) | 治疗驱动基因阳性肺癌的联用药物组合物 | |
| US20250295765A1 (en) | Drug combination for treating non-small cell lung cancer | |
| CN116370641A (zh) | 用于治疗消化系统恶性肿瘤的联用药物 | |
| Kato et al. | Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study | |
| JP2023502876A5 (enExample) | ||
| TW201922273A (zh) | 用於治療肝癌之組合物及方法 | |
| Kojima et al. | Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors | |
| US20230338521A1 (en) | Methods of treating cancer using a combination of a pd-1 antagonist, a chemoradiation therapy and a parp inhibitor | |
| Vansteenkiste et al. | Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model | |
| CN120437288A (zh) | 治疗卵巢癌的药物组合 | |
| Ettrich et al. | Nintedanib plus mFOLFOX6 as second‐line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo‐controlled, phase II TRICC‐C study (AIO‐KRK‐0111) | |
| JP2024527974A (ja) | 小細胞肺がんを治療する薬物の組み合わせ | |
| Camera et al. | MOMENTUM: a phase I trial investigating 2 schedules of capecitabine with aflibercept in patients with gastrointestinal and breast cancer | |
| CN118176021A (zh) | 抗ctla-4抗体给药方案 | |
| CN114159557A (zh) | 一种治疗肿瘤疾病的联合用药组合物及应用 | |
| WO2025103377A1 (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| Jones et al. | A randomized phase II trial of oral Topotecan versus Docetaxel in the second-line treatment of non–small-cell lung cancer | |
| CN112543637B (zh) | 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途 | |
| Tran et al. | Hoang-Quy Nguyen1, Khanh-Luan Tran2, Manh-Hung Vuong3 | |
| Adachi et al. | Clinical Phase I Study of TAS102/Irinotecan/Bevacizumab Combination Therapy in Japanese Patients With Unresectable Metastatic Colorectal Cancer (mCRC) | |
| Wategaonkar et al. | 185P Real-World outcomes with low-dose nivolumab across multiple tumor types in Western India: A retrospective analysis |